THE ATTEMPTS OF MIKHAIL BLAGOSKLONNY TO CURE AGING

Through technology, innovation and massive research, scientists have been able to make great discoveries. These have led to solutions of some of the worst nightmares that the world has seen and more challenges are yet to be solved. One of these is aging. Everyone wants to look and stay young and this has driven many people to undertake expensive remedies but at the end of the day, aging still catches up with people. This topic of aging has driven Mikhail Blagosklonny a renown oncologist to dedicate a substantial amount of his research to its study.

In his recent hypothesis, he proposes that Target Of Rapamycin (TOR) could be responsible for aging in organisms. He argues that TOR; a substance responsible for regulating the usage of substances such as amino acids, insulin and growth factors in the body results in over-stimulation of body cells making them fail to function adequately. As a result the various organs wear out thus causing aging. He recommends the use of rapamycin; a cancer drug in the treatment of aging. View Mikhail’s profile on Loop

Other interests of Blagosklonny include research on cancer, cell cycle, mitosis and molecular and cellular biology. He loves sharing his knowledge and has published over 250 peer reviewed articles. To further support spread of scientific knowledge, he co-founded Oncotarget. This is a weekly medical journal that publishes papers on various biomedical fields. It has a team of editors who review the papers to ensure that they are up to standard and credible.

Mikhail Blagosklonny has a strong education background in biomedical sciences. He was a student at First Pavlov States Medical University of St. Peterburg degree in internal medicine and a PhD in experimental medicine and cardiology.  At the institute he works on developing new methods of cancer prevention and treatment in an attempt to offer more options to cancer patients. He also has an extensive work experience having worked at the New York Medical College and the Ordway Research Institute in New York.  Check Mikhail’s profile in LinkedIn